AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2025
May 22, 2025
32159_dirs_2025-05-22_3eb6f567-5507-4ff9-8990-c4d4c1d2c8ab.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2025-05-20
Reporting Person: Fitzpatrick Alexander A (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-20 | Common Stock | M | 100000 | $5.58 | Acquired | 192582 | Direct |
| 2025-05-20 | Common Stock | S | 102969 | $14.0966 | Disposed | 89613 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-20 | Stock Option (Right to Buy) | $5.58 | M | 100000 | Disposed | 2034-01-01 | Common Stock (100000) | Direct |
Footnotes
F1: Includes 3,355 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024.
F2: The weighted average sale price for the transaction reported was $14.0966 and the range of prices were between $14.02 and $14.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: 25% of the shares subject to the option vested on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.